Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices 47759 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: David B. Winter, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4204, 

MSC 7812, Bethesda, MD 20892, 301–435– 

1152, dwinter@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 6, 2017. 

Anna Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–22140 Filed 10–12–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive Patent 

License: Use of Pharmaceutical and 

Biological Compositions Comprising 

Gram-Negative Bacteria for the Topical 

Treatment of Dermatological Diseases 

and Dermatological Conditions 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Institute of 

Allergy and Infectious Diseases, an 

institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Commercialization 

Patent License to practice the inventions 

embodied in the Patents and Patent 

Applications listed in the Summary 

Information section of this notice to 

Forte Biosciences, Inc. located in San 

Diego, California. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Institute of 

Allergy and Infectious Diseases’ 

Technology Transfer and Intellectual 

Property Office on or before October 30, 

2017 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

Exclusive Commercialization Patent 

License should be directed to: David 

Yang, Technology Transfer and 

Patenting Specialist, Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, National Institutes 

of Health, 5601 Fishers Lane, Suite 6D, 

Rockville, MD 20852–9804; Email: 

yangp3@nih.gov; Telephone: (240) 627– 

3413; Facsimile: (240) 627–3117. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

U.S. Provisional Application 62/ 

324,762, filed April 19, 2016, and PCT 

Patent Application PCT/US2017/ 

028133, filed April 17, 2017, both 

entitled ‘‘Use of Gram Negative Species 

to Treat Atopic Dermatitis’’ [HHS Ref. 

E–099–2016/0], and U.S. and foreign 

patent applications claiming priority to 

the aforementioned applications. 

The patent rights in these inventions 

have been assigned to the government of 

the United States of America. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to the 

following field of use: ‘‘Use of 

pharmaceutical and biological 

compositions comprising Gram-negative 

bacteria for the topical treatment of 

dermatological diseases and 

dermatological conditions’’. 

Atopic dermatitis (AD) is a common, 

recurrent, chronic inflammatory skin 

disease that is a cause of considerable 

economic and social burden. It is one of 

the most prevalent skin disorders, 

affecting ∼25% of children in developed 

and developing countries and is 

expected to continue to escalate. This 

increased rate of incidence has changed 

the focus of research on AD toward 

epidemiology, prevention, and 

treatment. 

The subject technology describes 

pharmaceutical and biological 

compositions comprising Gram-negative 

bacteria that can be developed into a 

topical treatment for atopic dermatitis 

(AD), as well as methods and kits using 

these compositions. 

NIAID scientists have recently 

identified probiotic strains of 

Roseomonas mucosa bacteria that were 

shown to be beneficial in a pre-clinical 

mouse model of AD. With this 

promising data, NIAID launched a phase 

I/II clinical trial in March 2017 (link; 

https://clinicaltrials.gov/ct2/show/ 

NCT03018275) and preliminary results 

from this ongoing study show that the 

technology may be highly effective at 

treating and reducing the symptoms of 

atopic dermatitis. If successfully 

developed, this invention would be the 

first live biotherapeutic product 

approved by the FDA for the treatment 

of AD. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Institute of Allergy and Infectious 

Diseases receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404. 

Complete applications for a license in 

the prospective field of use that are filed 

in response to this notice will be treated 

as objections to the grant of the 

contemplated Exclusive 

Commercialization Patent License 

Agreement. Comments and objections 

submitted to this notice will not be 

made available for public inspection 

and, to the extent permitted by law, will 

not be released under the Freedom of 

Information Act, 5 U.S.C. 552. 

Dated: October 4, 2017. 

Suzanne Frisbie, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2017–22148 Filed 10–12–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Senior Executive Service Performance 

Review Board 

AGENCY: Office of the Secretary, 

Department of Homeland Security 

(DHS). 

ACTION: Notice. 

SUMMARY: This notice announces the 

appointment of the members of the 

Senior Executive Service (SES) 

Performance Review Board (PRB) for 

DHS. The purpose of the PRB is to view 

and make recommendations concerning 

proposed performance appraisals, 

ratings, bonuses, pay adjustments, and 

other appropriate personnel actions for 

incumbents of SES, Senior Level and 

Senior Professional positions of the 

Department. 

DATES: The PRB members’ terms begin 

October 13, 2017. 

FOR FURTHER INFORMATION CONTACT: 

Elizabeth Haefeli, Office of the Chief 

Human Capital Officer, 

Elizabeth.Haefeli@hq.dhs.gov, or by 

telephone (202) 357–8164. 

SUPPLEMENTARY INFORMATION: Each 

Federal agency is required to establish 

one or more performance review boards 

to make recommendations, as necessary, 

in regard to the performance of senior 

executives within the agency. 5 U.S.C. 

4314(c). This notice announces the 

appointment of the members of the PRB 

for DHS. The purpose of the PRB is to 

review and make recommendations 

concerning proposed performance 


asabaliauskas on DSKBBXCHB2PROD with NOTICES